リポソームドキソルビシンの市場規模、シェア、成長分析：製品タイプ別、用途別、流通チャネル別、地域別 - 産業予測 2025～2032年

リポソームドキソルビシンの世界市場規模は2023年に12億米ドルと評価され、2024年の12億8,000万米ドルから2032年には21億米ドルに成長し、予測期間（2025～2032年）のCAGRは6.4%で成長する見通しです。

リポソームドキソルビシン市場は、肉腫の罹患率の上昇と、乳がん、卵巣がん、カポジ肉腫などさまざまながんの治療における薬剤の使用によって力強い成長を遂げています。リポソームに封入されたこの化学療法溶液は、現代のヘルスケアの進歩、医療費の増加、治療選択肢に関する患者の意識の高まりから恩恵を受けています。ジェネリック医薬品との競合やFDAの厳しい承認プロセスが課題となる一方で、官民双方からの投資拡大により市場全体の拡大が見込まれています。さらに、肝細胞がんの罹患率と生存率の上昇に加え、従来の治療に反応しない患者に対する効果的な代替療法へのニーズが高まっていることも、リポソームドキソルビシンの需要をさらに刺激し、市場は今後数年間で大きく成長すると考えられます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

リポソームドキソルビシン市場規模：製品タイプ別& CAGR（2025-2032）

• 市場概要
• リポドックス
• ドキシル
• ミオセット

リポソームドキソルビシン市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 乳がん
• 卵巣がん
• 多発性骨髄腫
• カポジ肉腫
• その他のがん

リポソームドキソルビシン市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

リポソームドキソルビシン市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Johnson & Johnson（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Pfizer Inc.（USA）
• Merck & Co., Inc.（USA）
• Cipla Inc.（India）
• Cadila Pharmaceuticals（India）
• SRS Pharmaceuticals Pvt. Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Gilead Sciences, Inc.（USA）
• Baxter International Inc.（USA）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Mylan N.V.（USA）
• Sanofi S.A.（France）
• Eli Lilly and Company（USA）
• GlaxoSmithKline plc（UK）
• AstraZeneca plc（UK）
• Amgen Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）

結論と提言

Global Liposomal Doxorubicin Market size was valued at USD 1.2 billion in 2023 and is poised to grow from USD 1.28 billion in 2024 to USD 2.1 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The liposomal doxorubicin market is experiencing robust growth driven by the rising incidence of sarcoma and the drug's use in treating various cancers such as breast, ovarian, and Kaposi sarcoma. This chemotherapy solution, encapsulated in liposomes, benefits from modern healthcare advancements, increased healthcare expenditures, and heightened patient awareness regarding treatment options. While competition from generic medications and stringent FDA approval processes pose challenges, overall market expansion is anticipated due to growing investment from both public and private sectors. Additionally, the escalating need for effective alternatives for patients unresponsive to traditional treatments, alongside the rising incidence and survival rates of hepatocellular carcinoma, further stimulates demand for liposomal doxorubicin, positioning the market for substantial growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liposomal Doxorubicin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liposomal Doxorubicin Market Segments Analysis

Global Liposomal Doxorubicin Market is segmented by Product Type, Application, Distribution Channel and region. Based on Product Type, the market is segmented into Lipodox, Doxil and Myocet. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, Multiple Myeloma, Kaposi's Sarcoma and Other Cancers. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liposomal Doxorubicin Market

The Global Liposomal Doxorubicin market is predominantly driven by its application in the treatment of breast cancer, a disease that is rapidly escalating in prevalence across the globe. The surge in innovative formulations has significantly enhanced the drug's appeal and adoption for breast cancer therapy. Several other factors are expected to propel market growth in the coming years, including a rising demand for targeted therapies, increased utilization of chemotherapy, and heightened investments from private sectors focused on this treatment. Additionally, robust government support for the healthcare industry plays a vital role in advancing the market's global expansion.

Restraints in the Global Liposomal Doxorubicin Market

The global liposomal doxorubicin market could face limitations due to potential adverse effects associated with the medication. Patients may experience various complications such as an increased risk of infections, difficulty in breathing, pallor, unexplained bruising, frequent nosebleeds, fatigue, and weakness both prior to and following treatment. Additionally, symptoms such as painful red or peeling skin on the hands and feet, significant weight loss, diarrhea, and generalized weariness may arise. These side effects could result in hesitancy among patients and healthcare providers, ultimately restraining the market's growth and acceptance in the treatment landscape.

Market Trends of the Global Liposomal Doxorubicin Market

The Global Liposomal Doxorubicin market is witnessing significant growth, driven primarily by the increasing incidence of breast cancer, which accounts for one in four female cancer diagnoses globally, according to the International Agency for Research on Cancer (IARC). As liposomal formulations enhance the therapeutic efficacy and reduce the cardiotoxicity associated with conventional doxorubicin, they are gaining traction among oncologists and patients alike. Innovations in drug delivery systems, coupled with rising healthcare expenditures and a surge in awareness regarding targeted cancer therapies, position liposomal doxorubicin as a preferred choice in chemotherapeutic regimens, effectively meeting the growing demand for safer and more effective cancer treatments worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Liposomal Doxorubicin Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Lipodox
• Doxil
• Myocet

Global Liposomal Doxorubicin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Ovarian Cancer
• Multiple Myeloma
• Kaposi's Sarcoma
• Other Cancers

Global Liposomal Doxorubicin Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Liposomal Doxorubicin Market Size & CAGR (2025-2032)

• North America (Product Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SRS Pharmaceuticals Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations